SCHEMBL4881687

SCHEMBL4881687

CC(C)(C)[Si](C)(C)OCCN(C#N)c1ccc(NC(=O)c2nccnc2C(=O)Nc2ccc(C#N)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.37
MAPT P10636 2/20 0.37
MLYCD O95822 1/20 0.37
TP53 P04637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NAMPT P43490 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
POLB P06746 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880731 0.93 MAPT (0.36) SIRT2MAPTTP53ALDH1A1NPC1
SCHEMBL4881302 0.92 KMT2A (0.38) SIRT2MAPTTP53ALDH1A1NPC1
SCHEMBL4878081 0.86 KMT2A (0.38) MAPTTP53ALDH1A1NPC1PKM
SCHEMBL4881051 0.85 RAB9A (0.38) MAPTTP53ALDH1A1NPC1RAB9A
SCHEMBL4882033 0.84 MLYCD (0.42) MAPTMLYCDTP53ALDH1A1NPC1
SCHEMBL3614731 0.82 RAB9A (0.39) SIRT2MAPTALDH1A1NPC1RAB9A
SCHEMBL4880879 0.80 RAB9A (0.37) SIRT2MAPTTP53ALDH1A1NPC1
SCHEMBL3623718 0.78 NPC1 (0.37) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3609334 0.77 PRSS12 (0.38) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4886038 0.77 KMT2A (0.40) MAPTMLYCDTP53ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 SIRT2 2081/4885MAPT 4803/4885MLYCD 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.